according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04/04/2023

 5.0
 09/30/2023
 785424-00018
 Date of first issue: 06/28/2016

#### **SECTION 1. IDENTIFICATION**

Product name : Orbifloxacin Liquid Formulation

Other means of identification : No data available

### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

#### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure (Oral)

: Category 2 (Eye)

#### **GHS** label elements

Hazard pictograms :

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Eye) through prolonged or

repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 785424-00018 Date of first issue: 06/28/2016 5.0

### Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

#### Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

#### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Propylene glycol	1,2-Propanediol	57-55-6	>= 10 - < 30 *
Orbifloxacin	No data availa- ble	113617-63-3	>= 1 - < 5 *
Silicon dioxide	Silica	7631-86-9	>= 1 - < 5 *
Lactic acid	Propanoic acid, 2-hydroxy-	50-21-5	>= 1 - < 5 *
Sodium hydroxide	Caustic soda	1310-73-2	>= 1 - < 2 *

\* Actual concentration or concentration range is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. Suspected of damaging the unborn child.

Most important symptoms

and effects, both acute and

delayed

In case of eye contact

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

according to the Hazardous Products Regulations



## Orbifloxacin Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 785424-00018 Date of first issue: 06/28/2016 5.0

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Hazardous combustion prod-

ucts

Exposure to combustion products may be a hazard to health.

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures See Engineering measures under EXPOSURE

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Propylene glycol	57-55-6	TWA (Va- pour and aerosols)	50 ppm 155 mg/m³	CA ON OEL
		TWA (aero- sol)	10 mg/m <sup>3</sup>	CA ON OEL
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Silicon dioxide	7631-86-9	TWAEV (respirable dust)	6 mg/m³	CA QC OEL
Sodium hydroxide	1310-73-2	(c)	2 mg/m³	CA AB OEL
		С	2 mg/m³	CA BC OEL
		С	2 mg/m³	CA QC OEL
		С	2 mg/m³	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Filter type : Combined particulates and organic vapor type Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : suspension

Color : light brown

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : Oxidizing agents

Hazardous decomposition : No hazardous de

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

### **Acute toxicity**

Not classified based on available information.

#### **Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

**Components:** 

Propylene glycol:

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 200 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg Application Route: Intramuscular

LD50 (Rat): 233 mg/kg

Application Route: Intravenous

LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Silicon dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

#### Skin corrosion/irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : No skin irritation

**Components:** 

Propylene glycol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Silicon dioxide:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Sodium hydroxide:

Result : Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : Mild eye irritation

**Components:** 

Propylene glycol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Orbifloxacin:

Species : Rabbit

Result : Mild eye irritation
Method : Draize Test

Silicon dioxide:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

Sodium hydroxide:

Result : Irreversible effects on the eye Remarks : Based on skin corrosivity.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

#### Respiratory sensitization

Not classified based on available information.

**Product:** 

Test Type : Magnusson-Kligman-Test

Routes of exposure : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

**Components:** 

Propylene glycol:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Orbifloxacin:

Test Type : Maximization Test

Routes of exposure : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Lactic acid:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Sodium hydroxide:

Test Type : Human repeat insult patch test (HRIPT)

Routes of exposure : Skin contact
Result : negative

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Propylene glycol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Application Route: Intraperitoneal injection

Result: negative

Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intraperitoneal injection

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat

Cell type: Liver cells Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Silicon dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

#### Carcinogenicity

Not classified based on available information.

#### Components:

#### Propylene glycol:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

#### Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

### Silicon dioxide:

Species : Rat
Application Route : Ingestion
Exposure time : 103 weeks
Result : negative

#### Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

#### Reproductive toxicity

Suspected of damaging the unborn child.

#### **Components:**

#### Propylene glycol:

Effects on fertility: Test Type: Two-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

Result: negative

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

**Application Route: Ingestion** 

Result: negative

Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body

weight

Result: No adverse effects.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high

maternally toxic doses

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development.,

Embryotoxic effects and adverse effects on the offspring were

detected only at high maternally toxic doses, Reduced

maternal body weight gain.

Test Type: Development

Species: Dog

Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development., Skeletal

malformations.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Silicon dioxide:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Application Route: Ingestion

Result: negative

#### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

#### **Product:**

Target Organs : Eye

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

### **Product:**

Species : Dog

NOAEL : 22.5 mg/kg LOAEL : 37.5 mg/kg Application Route : Oral Exposure time : 30 Days

Symptoms : Gastrointestinal disturbance

Species : Dog LOAEL : 75 mg/kg Application Route : Oral Exposure time : 10 Days

Symptoms : Salivation, Gastrointestinal disturbance, Vomiting

Species : Cat
LOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Eye

Symptoms : Salivation, Lachrymation, Gastrointestinal disturbance, Liver

disorders

#### **Components:**

### Propylene glycol:

Species : Rat, male

NOAEL : >= 1,700 mg/kg

Application Route : Ingestion

Exposure time : 2 y

#### Orbifloxacin:

Species : Rat

NOAEL : 20 mg/kg

LOAEL : 80 mg/kg

Application Route : Oral

Exposure time : 3 Months

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse

NOAEL : 80 mg/kg

LOAEL : 250 mg/kg

Application Route : Oral

Exposure time : 3 Months

Species : Juvenile dog
NOAEL : 50 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Heart, Bone

Symptoms : Gastrointestinal disturbance

Remarks : mortality observed

Species : Juvenile dog
NOAEL : 2 mg/kg
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 37.5 mg/kg Application Route : Oral Exposure time : 30 Days

Species : Cat

NOAEL : 7.5 mg/kg

LOAEL : 22.5 mg/kg

Application Route : Oral

Exposure time : 1 Months

Symptoms : Gastrointestinal disturbance

Silicon dioxide:

Species : Rat NOAEL : 1.3 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 13 Weeks

Lactic acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Remarks : Based on data from similar materials

Species : Rat LOAEL : 886 mg/kg

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 785424-00018 Date of first issue: 06/28/2016 5.0

Application Route Skin contact Exposure time 13 Weeks

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

Orbifloxacin:

Ingestion Symptoms: central nervous system effects, Gastrointestinal

disturbance, liver function change, anaphylaxis, Rash

Remarks: May cause photosensitization.

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

**Components:** 

Propylene glycol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l

Exposure time: 7 d

NOEC (Pseudomonas putida): > 20,000 mg/l Toxicity to microorganisms

Exposure time: 18 h

Silicon dioxide:

LC50 (Danio rerio (zebra fish)): > 10,000 mg/l Toxicity to fish

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 1,000 mg/l

Exposure time: 24 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Desmodesmus subspicatus (green algae)): > 10,000

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

NOEC (Desmodesmus subspicatus (green algae)): 10,000

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

Persistence and degradability

**Components:** 

Propylene glycol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 98.3 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

### **Bioaccumulative potential**

#### **Components:**

### Propylene glycol:

Partition coefficient: n-

octanol/water

: log Pow: -1.07

Method: Regulation (EC) No. 440/2008, Annex, A.8

Lactic acid:

Partition coefficient: n-

octanol/water

log Pow: -0.62

Mobility in soil

No data available

Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

#### **Disposal methods**

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

### **UNRTDG**

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

### **IMDG-Code**

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **Domestic regulation**

#### TDG

Not regulated as a dangerous good

## Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA ON OEL : Ontario Table of Occupational Exposure Limits made under

the Occupational Health and Safety Act.

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / C : Ceiling limit

CA AB OEL / (c) : ceiling occupational exposure limit

CA BC OEL / C : ceiling limit

CA ON OEL / TWA : Time-Weighted Average Limit (TWA)
CA QC OEL / TWAEV : Time-weighted average exposure value

CA QC OEL / C : Ceiling

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration: ICAO - International Civil Aviation Organization: IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transporta-

according to the Hazardous Products Regulations



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 5.0 09/30/2023 785424-00018 Date of first issue: 06/28/2016

tion of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Complie the Material Sa

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8